An Indian pharma company that specializes in Contrast media Intermediates that are compounds used in CT scans and MRI, Artificial Sweeteners, and APIs, announced their Q3FY25 results with a 91% YoY increase in revenue and a 208 % increase in net profits.
Share Price Movement
With a market capitalization of ₹10,969 Cr, the share of Blue Jet Healthcare opened at ₹573, and after the declaration of results, it hit 10% Upper circuit and a new 52-week high at ₹ 630. The past month’s return for the stock is 13% and the 1-year return stands at a staggering 65%.
Q3FY25 Results
The company reported a 91% YoY increase in revenue from ₹16.67 Cr in Q2FY24 to ₹31.83 Cr in Q3FY25. Their Net profit too saw a significant upside with a 208 % YoY increase from ₹3.21 Cr to ₹9.89 Cr for the same period.
On a QoQ basis, the company reported an increase of 53% in revenue from ₹ 20.82 Cr in the previous quarter, and their net profits saw an increase of 70% from ₹ 5.83 Cr for the same period.
Updates from the Company
The Board has approved investments of up to ₹40 Cr for setting up of Research and Development Facility
During the previous year, an incident at the Mahad facility resulted in a loss of damaged assets and compensation to employees aggregating to ₹9.73 Cr accounted for as exceptional items by the company.
The Company changed its accounting method for depreciation from the Written Down Value (WDV) to the Straight-Line Method (SLM).
About the Company
Blue Jet Healthcare is a global, science-led, pharmaceutical company that evolved as a Strategic Partner for the Collaboration, Development & Manufacturing of advanced Pharmaceutical Intermediates and API.
Having 53 years of history, its know-how and expertise have grown over many years in the development, scale, and commercialization which has now been expanded to include contract development.
Written By Abhishek Das
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses.
